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The toxicological and redox profiles of MDMA and its major metabolites (MDA, R-methyldopamine,
N-methyl-R-methyldopamine, 6-hydroxy-R-methyldopamine, 3-methoxy-R-methyldopamine) were studied
to establish a structure-toxicity relationship and determine their individual contribution to cell death
induction by apoptosis and/or necrosis. The results of the comparative toxicity study, using undifferentiated
PC12 cells, strongly suggest that the metabolites possessing a catecholic group are more toxic to the
cells than MDMA and metabolites with at least one protected phenolic group. Redox studies reveal that
an oxidative mechanism seems to play an important role in metabolite cytotoxicity. Nuclear features of
apoptosis and/or necrosis show that most of the metabolites, particularly N-methyl-R-methyldopamine,
induce cell death by apoptosis, largely accompanied by necrotic features. No significant differences were
found between MDMA and the metabolites, concerning overall characteristics of cell death. These results
may be useful to ascertain the contribution of metabolism in MDMA neurotoxicity molecular mechanisms.
Introduction
3,4-Methylenedioxymethamphetamine (MDMA, “ecstasy”,
16) is a ring-substituted phenethylamine derivative widely used
as a recreational drug. The abuse of this group of amphetamine-
like designer drugs is increasing among young adults, being at
present a serious public health problem (1, 2). The toxicity
related to the misuse of this drug is extensively reported in recent
literature, but the molecular mechanisms involved remain largely
unknown. Among several biological targets, the neurotoxic (3),
nephrotoxic (4), hepatotoxic (5), and cardiovascular (6) effects
of MDMA were extensively studied in Vitro and in ViVo.
The research on the biotransformation reactions of xenobi-
otics, which play a major role in influencing the nature, intensity,
and duration of wanted and unwanted effects, is an important
task in the medicinal chemistry field (7). A majority of the
investigation has been based on the overall effects induced by
the use of the drug, but little attention has been given to the
putative activities of the metabolites themselves. Several recent
studies suggest that part of the toxicity ascribed to MDMA can
be related to the formation of metabolites with higher activity
(8-10). Several MDMA metabolic pathways have been pro-
posed and reported (11-12), with the N-demethylation to 3,4-
methylenedioxyamphetamine (MDA, 11), also as a recreational
drug, and the simultaneous or subsequent O-demethylenation
to 3,4-dihydroxyamphetamine (R-methyldopamine, R-MeDA,
19) and 3,4-dihydroxymethamphetamine (N-methyl-R-methyldop-
amine, N-Me-R-MeDA, 21) being the most significant ones. It
has also been assumed that the catecholic compounds 19 and
21 can undergo subsequent O-methylation mediated by catechol
O-methyltranferase (COMT) to 4-hydroxy-3-methoxyamphet-
amine (3-methoxy-R-methyldopamine, 3-O-Me-R-MeDA, 13)
and 4-hydroxy-3-methoxymethamphetamine (Figure 1).
Aromatic hydroxylation has also been established as an im-
portant biotransformation step in in ViVo metabolism of MDMA
in rats. This reaction can occur at the remaining positions of
the aromatic ring, but the one occurring at C6 is the most reactive
one. The resulting compound 2,4,5-trihydroxyamphetamine (6-
hydroxy-R-methyldopamine, 6-OH-R-MeDA, 20) is structurally
similar to 6-hydroxydopamine (a potent neurotoxin obtained by
in ViVo aromatic hydroxylation of dopamine) (13, 14). All
compounds possessing a catecholic group can undergo further
conjugation with other molecules like sulfate, glucuronide and
thiol-containing endogenous substances (glutathione, cysteine,
and N-acetylcysteine).
Animals exposed to MDMA show acute and long-term
neurotoxic effects, causing irreversible damage to the central
nervous system. Characterization of the in ViVo and in Vitro
MDMA-induced neurotoxicity was widely accomplished
(15-17), although the molecular mechanisms involved remain
to be fully elucidated. Previously published studies suggested
that bioactivation occurs after the administration of amphet-
amines, mediating a series of neurotoxic effects (18-20).
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MDMA is a monoaminergic neurotoxin in both serotonin
(5HT) and dopamine nerve terminals, depending on the animal
species and conditions of administration. The neurotoxicity has
been largely associated to a modification of the serotonergic
function, namely, through an acute release of serotonin from
central neurons, followed by prolonged depletion and structural
neuronal damage (21-23). There is also considerable evidence
that MDMA shows marked effects on dopamine release and
can damage dopamine axon terminals, which could play a major
role in some behavioral, mental, and thermal changes in animals
(24, 25).
Cell death by apoptosis or necrosis has been proposed to be
involved in amphetamine-induced neurodegeneration (26, 27).
The activation of these pathways seems to be closely related to
the occurrence of oxidative stress in the cellular medium,
through redox cycles, which is intimately linked to the metab-
olism of MDMA and catecholamine (auto)oxidation (10, 28).
Nonconjugated metabolites of MDMA are present in blood,
brain, liver, feces, and urine for a 24-hour period following drug
administration (11). It is generally accepted that one or more
metabolites of MDMA or MDA may be responsible for
neurotoxic effects because direct intracerebral injection of the
drugs failed to reproduce the neurotoxicity revealed after
peripheral administration (29). As MDMA does not seem to be
neurotoxic, the evaluation of the metabolite’s toxic effects is
essential for the elucidation of the molecular mechanisms
involved. However, there is controversy regarding the specific
role of the metabolites. Intracerebroventricular administration
of R-MeDA, N-Me-R-MeDA, and 3-O-Me-R-MeDA failed to
produce the same neurotoxic features on central serotoninergic
and dopaminergic systems induced by peripherally administered
MDMA (18, 30); nonetheless, other neurochemical effects were
determined, and alterations were detected for the same metabo-
lites, specially for 6-OH-R-MeDA (18, 31, 32).
In order to examine the hypothesis that the metabolites can
contribute to the neurotoxicity of the parent compound, the
cytotoxic potential of MDMA and five of its metabolites was
investigated. The research project includes the synthesis of the
main described metabolites of MDMA through standard syn-
thetic methods and the evaluation of their cytotoxic profiles by
using undifferentiated PC12 cells in culture, a well-established
in Vitro model of catecholaminergic neurons (33-35). Cell
viability was assessed after incubation for 24 h with increasing
concentrations of the compounds in order to determine the IC50
values. Because oxidative pathways have been proposed to play
an important role in the toxicity profile of this type of
compounds, the relationship between the redox profile and
cytotoxicity was also studied. Accordingly, to get new insights
on the molecular mechanisms underlying the biological activi-
ties, the redox properties of the drug and metabolites were
determined using different electrochemical techniques.
Because MDMA-induced cell damage is related to pro-
grammed cell death in serotoninergic and neocortical neurons
(36, 37), assays of chromatin fragmentation/condensation were
performed in PC12 cells in order to define drug-induced cell
death as apoptotic and/or necrotic. To the best of our knowledge,
there are no reports of apoptosis-like events induced by the
MDMA metabolites in dopaminergic-like neurons.
Experimental Procedures
Materials and Solutions. PC12 cells were obtained from ATCC
(Manassas, VA). 3,4-Dihydroxybenzaldehyde, 3,4-dimethoxyben-
zaldehyde, 4-hydroxy-3-methoxybenzaldehyde, 2,4,5- trimethoxy-
Figure 1. Proposed major metabolic pathways of MDMA; the numbered compounds correspond to the metabolites synthesized and used in the
toxicological assays.
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benzaldehyde, bromochloromethane, potassium carbonate, benzyl
chloride, cesium carbonate, ammonium acetate, nitroethane, anhy-
drous magnesium sulfate, lithium aluminum hydride (1 M solution
in tetrahydrofuran), ethyl chloroformate, boron tribromide (1 M
solution in dichloromethane), 10% platinum in carbon, RPMI 1640
medium (modified with L-glutamine and 25 mM HEPES), strep-
tomycin, penicillin, MTT, poly-L-lysine and propidium iodide, and
all dry solvents were purchased from Sigma-Aldrich Quı´mica S.A.
(Sintra, Portugal). Syto-13 was obtained from Molecular Probes
(Eugene, OR). Horse serum and fetal bovine serum were purchased
from BioChrom KG (Berlin, Germany). All other reagents and
solvents were pro analysis grade and were acquired from Merck
(Lisbon, Portugal). Deionized water (conductivity <0.1 íS cm-1)
was used in all experiments. The gases, hydrogen, argon and
nitrogen, were of the highest grade available. All reagents were
used without further purification.
To perform electrochemical measurements, 10 mM stock solu-
tions of the compounds were made by dissolving an appropriate
amount in water. The voltammetric working solutions were
prepared, in an electrochemical cell, by diluting 100 íL of the stock
solution in 10 mL of supporting electrolyte to get a final concentra-
tion of 0.1 mM. The pH 7.3 supporting electrolyte, used for
voltammetric determinations, was prepared by diluting 6.2 mL of
0.2 M dipotassium hydrogen phosphate and 43.8 mL of 0.2 M
potassium dihydrogen phosphate to 100 mL.
Apparatus and Other Analytical Conditions. 1H and 13C NMR
data were acquired, at room temperature, on a Bru¨ker AMX 300
spectrometer operating at 300.13 and 75.47 MHz, respectively.
Chemical shifts are expressed in ä (ppm) values, relative to
tetramethylsilane (TMS) (as internal reference); coupling constants
(J) are given in Hz. Dimethyl sulfoxide-d6 was used as solvent
unless specified in spectroscopic data. Assignments were also made
from DEPT (distortionless enhancement by polarization transfer)
experiments (values in italic). Electron impact mass spectra
(EI-MS) were obtained on a VG AutoSpec instrument; data are
reported as m/z (% of relative intensity for the most important
fragments). Melting points were measured on a Ko¨fler microscope
(Reichert Thermovar) and were uncorrected. Analytical thin-layer
chromatography (TLC) was carried out on 0.2 mm silica gel 60
F254 plates.
The purity of the final products (>95% purity) was verified using
two different high-performance liquid chromatography (HPLC)
systems, one equipped with a UV detector (DAD) and the other
with an electrochemical detector. First, chromatograms were
obtained in an HPLC/DAD system, a Jasco instrument (pumps
model 880-PU and solvent mixing model 880-30, Tokyo, Japan),
equipped with a commercially prepacked Nucleosil RP-18 analytical
column (250 mm  4.6 mm, 5 ím, Macherey-Nagel, Du¨ren,
Germany), and UV detection (Jasco model 875-UV) at the
maximum wavelength determined by the analysis of the UV
spectrum of each compound. The isocratic mobile phase consisted
of 10 mM aqueous ammonium acetate (adjusting the final pH to 3
with hydrochloric acid) with 10% acetonitrile, at a flow rate of 1
mL/min at room temperature. The chromatographic data was
processed in a Compaq computer, fitted with CSW 1.7 software
(DataApex, Czech Republic).
A Waters 2690 Alliance system equipped with a CONCORDE
Electrochemical Detector (Waters Corporation, Milford, USA) was
also used. The electrochemical cell was a VT-03 flow cell (Antec
Leyden, Zoeterwoude, Netherlands) with a confined wall-jet design
in a three-electrode configuration: a 2 mm diameter glassy carbon
working electrode, an in-situ Ag/AgCl reference electrode, and a
stainless steel auxiliary electrode. The electrochemical detector was
operated in oxidative amperometric mode with the working
potentials between -100 mV and +1200 mV. The HPLC separation
was carried out in a reverse phase LC-18-S Supelcosil analytical
column (150 mm  4.6 mm, 5 ím, Supelco, Bellefonte, USA);
100 mM sodium acetate (pH 4.3)/methanol (10:3) was used as
mobile phase, in isocratic mode at 1 mL/min flow rate. Chromato-
grams were acquired in a Millenium 32 Chromatography Manager
(Waters Corporation, Milford, USA).
Electrochemical data were obtained using an Autolab PGSTAT
12 potentiostat/galvanostat (Eco-Chemie, Netherlands) and a one-
compartment glass electrochemical cell. Voltammetric curves were
recorded at room temperature using a three-electrode system. A
glassy carbon working electrode (GCE) (d ) 2 mm), a platinum
wire counter electrode, and an Ag/AgCl saturated KCl reference
electrode were used. A Metrohm E520 pH-meter with glass
electrode was used for pH measurements (Metrohm, Switzerland).
Synthesis of Metabolites. Synthesis of Aldehydes 1 and 5. 3,4-
Methylenedioxybenzaldehyde (1). Because piperonal (1) is not
commercially available in Portugal, it was synthesized by an
adaptation of a previously described procedure (38). The dioxole
ring was closed after the reaction of the starting material 3,4-
benzaldehyde with bromochloromethane and using cesium carbon-
ate as a catalyst.
3,4-Dibenzyloxybenzaldehyde (5). Briefly, 3,4-benzaldehyde or
protocatechualdehyde (5.0 g, 36.2 mmol) was dissolved in N,N-
dimethylformamide (DMF) (80 mL). Potassium carbonate (20.0 g,
144.9 mmol) and benzyl chloride (9.6 mL, 83.5 mmol) were then
added to the solution, and the resulting suspension was stirred and
refluxed for 5 h. The remaining residue was filtered and the solution
poured on cold water/ice and acidified with HCl (pH 4). The yellow
precipitate produced was filtered, washed with cold water, and
identified as compound 5 (yield: 96%). The spectroscopic data is
in accordance with an article published earlier (39).
General Synthetic Procedure for Obtaining â-Methyl-â-
nitrostyrenes (6-10). The synthetic method used to obtain these
compounds was an adaptation of references published earlier (38,
40, 41) with only minor modifications. The corresponding benzal-
dehyde (1-5), with the aromatic substitution pattern of the target
compound, (30.0 mmol) and ammonium acetate (7.5 mmol) were
dissolved in nitroethane (50 mL) and refluxed for 6 h. After cooling
the reaction mixtures to room temperature, the solvent was partially
evaporated, diluted with diethyl ether, and washed twice with 100
mL of water. The organic layers were dried over anhydrous mag-
nesium sulfate, filtered, and concentrated. The remaining residues
were recrystallized from diethylether/petroleum ether (40-60 °C)
or from methanol/water to yield yellow to orange solids.
The reactions were all followed by thin layer chromatog-
raphy (TLC). The synthesized â-methyl-â-nitrostyrene derivatives
(6-10) were identified by both NMR and EI-MS. The compounds
were systematically characterized in this work, even though some
of them had been previously reported (11, 42, 43). The data of the
remaining compound used in this study (6) is described elsewhere
(44).
3,4-Dimethoxy-â-methyl-â-nitrostyrene (7). Yield 95%; 1H
NMR ä: 2.44 (3H, s, CH3), 3.80 (3H, s, 3-OCH3), 3.82 (3H, s,
4-OCH3), 7.08 (1H, d, J ) 8.5, H (5)), 7.22 (1H, s, H (2)), 7.23
(1H, d, J ) 8.5, H (6)), 8.08 (1H, s, H(R)); 13C NMR ä: 14.0
CH3, 55.6 (4-OCH3), 55.7 (3-OCH3), 111.8, 113.9 C (2) and C
(5), 124.3 C (6), 124.4 C (1), 133.8 C(R), 145.6 C(â), 148.7 C (4),
150.7 C (3); EI-MS m/z (%): 223 (M+¥, 100), 176 (78), 165 (22),
161 (37), 146 (47), 131 (46), 119 (36), 103 (37), 91 (47), 77 (38),
65 (34); mp 71-72 °C (lit (43). mp 72-74 °C).
4-Hydroxy-3-methoxy-â-methyl-â-nitrostyrene (8). Yield 98%;
1H NMR ä: 2.44 (3H, s, CH3), 3.81 (3H, s, OCH3), 6.89 (1H, d,
J ) 8.2, H (5)), 7.12 (1H, dd, J ) 8.2; 1.9, H (6)), 7.20 (1H, d, J
) 1.9, H (2)), 8.05 (1H, s, H(R)), 9.85 (1H, bs, OH); 13C NMR ä:
14.0 CH3, 55.7 (OCH3), 114.8, 115.9 C (2) and C (5), 123.0 C (1),
124.8 C (6), 134.2 C(R), 144.7 C(â), 147.7 C (4), 149.2 C (3);
EI-MS m/z (%): 209 (M+¥, 100), 162 (81), 147 (53), 131 (33),
119 (30), 103 (84), 91 (56), 77 (36), 65 (32); mp 97-99 °C (lit
(42). mp 100-101 °C).
2,4,5-Trimethoxy-â-methyl-â-nitrostyrene (9). Yield 92%; 1H
NMR ä: 2.39 (3H, s, CH3), 3.74 (3H, s, 2-OCH3), 3.88 (6H, s, 4-
and 5-OCH3), 6.79 (1H, s, H (3)), 7.01 (1H, s, H (6)), 8.20 (1H, s,
H(R)); 13C NMR ä: 14.1 CH3, 56.0, 56.2, 56.4 (3OCH3), 97.5 C
(3), 111.1, 113.3 C (1) and C (6), 128.8 C(R), 142.5 C (2), 145.1
C(â), 152.5 C (4), 153.9 C (5); EI-MS m/z (%): 253 (M+¥, 100),
206 (64), 191 (40), 177 (36), 163 (19), 149 (15), 121 (17), 77 (16),
69 (16); mp 93-95 °C.
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3,4-Dibenzyloxy-â-Methyl-â-nitrostyrene (10). Yield 79%; 1H
NMR ä: 2.32 (3H, s, CH3), 5.20 (2H, s, 3-OCH2), 5.22 (2H, s,
4-OCH2), 7.20 (2H, m, H (2) and H (5)), 7.33-7.45 (11H, m, phenyl
and H (6)), 8.03 (1H, s, H(R)); 13C NMR ä: 13.9 CH3, 69.8, 70.0
(2CH2), 113.9, 116.2 C (2) and C (5), 124.6 C (1), 124.9 C (6),
127.6-128.5 (10CHAr), 133.5 C(R), 136.9 (2CAr), 145.7 C(â),
147.8 C (3), 150.1 C (4); EI-MS m/z (%): 375 (M+¥, 20), 284 (8),
181 (10), 91 (100), 65 (13); mp 107-109 °C (lit (45). mp 103-
105 °C).
General Synthetic Procedure for the Reduction of Nitrosty-
rene Intermediates. The method applied for the synthesis of
compounds 11-15 was a modification of those described earlier
(40, 45). Therefore, a solution of the appropriate â-methyl-â-
nitrostyrene derivative (6-10) (8 mmol) in anhydrous tetrahydro-
furan (THF) (30 mL) was added dropwise to a stirred suspension
of lithium aluminum hydride (20 mmol) in anhydrous THF (50
mL) under nitrogen (N2). The reaction was stirred, heated under
reflux for 4 h, and then allowed to cool to room temperature. The
excess LiAlH4 was decomposed and the reaction quenched by the
smooth addition of cold water/ice with vigorous stirring. The
inorganic residue was removed by vacuum filtration; the solvent
was dried under anhydrous magnesium sulfate, evaporated, and the
residue diluted with diethyl ether and extracted with aqueous HCl
(3  100 mL of a 2 M solution). The acidic extract was alkalinized
with a NaOH solution and extracted with diethyl ether (3  100
mL). The organic layer was dried over anhydrous magnesium
sulfate, filtered and concentrated to yield light brown oils.
When necessary for the systematic characterization of the
compounds, the phenethylamine derivatives were isolated as salts
(due mainly to their stability and simple of handling). Hence, the
hydrochloride salts were prepared by acidifying the remaining
residues with methanolic or ethanolic HCl and diluting with diethyl
ether to obtain a white or almost white solid.
The identification of several of the amphetamine derivatives
(11-15) had been previously reported (10, 11, 43, 45-48). Never-
theless, some structural data was insufficiently accomplished, and
the spectroscopic characterization was thoroughly performed in this
work. For the accurate 1H NMR assignment of the (CH2CH)CH3
group in all of the amphetamine derivatives, the spectra were also
acquired in CDCl3 and D2O.
(R,S)-3,4-Dimethoxyamphetamine Hydrochloride (12). Yield
56%; 1H NMR ä: 1.11 (3H, d, CH3), 2.61 (1H, dd, J ) 13.4; 8.7,
CH2), 2.93 (1H, dd, J ) 13.4; 5.4, CH2), 3.36 (1H, m, CH), 3.72
(3H, s, 3-OCH3), 3.75 (3H, s, 4-OCH3), 6.73 (1H, dd, J ) 8.1; 1.8,
H (6)), 6.85 (1H, d, J ) 1.8, H (2)), 6.89 (1H, d, J ) 8.2, H (5)),
8.11 (3H, bs, NH3+); 13C NMR ä: 17.6 CH3, 39.6 CH2, 48.0 CH,
55.4, 55.5 (2OCH3), 111.8, 112.9 C (2) and C (5), 121.2 C (6),
129.0 C (1), 147.6 C (3), 148.7 C (4); EI-MS m/z (%): 195 (M+¥,
5), 162 (7), 152 (95), 137 (17), 121 (6), 107 (14), 91 (12), 83 (100),
65 (15); mp 146-148 °C (lit (43). mp 145-148 °C).
(R,S)-4-Hydroxy-3-methoxyamphetamine Hydrochloride (13).
Yield 35%; 1H NMR ä: 1.10 (3H, d, CH3), 2.56 (1H, dd, J )
13.5; 8.6, CH2), 2.86 (1H, dd, J ) 13.4; 5.5, CH2), 3.38 (1H, m,
CH), 3.75 (3H, s, 3-OCH3), 6.60 (1H, dd, J ) 8.0; 1.8, H (6)),
6.72 (1H, d, J ) 8.0, H (5)), 6.79 (1H, d, J ) 1.8, H (2)), 7.99
(3H, bs, NH3+), 8.91 (1H, bs, 4-OH); 13C NMR ä: 17.7 CH3, 39.5
CH2, 48.2 CH, 55.5 (OCH3), 113.2, 115.5 C (2) and C (5), 121.5
C (6), 127.3 C (1), 145.4 C (4), 147.6 C (3); EI-MS m/z (%): 181
(M+¥, 7), 138 (100), 122 (19), 94 (20), 89 (12), 77 (13), 65 (12);
mp 245 °C (dec) (lit (48). mp 244-246 °C).
(R,S)-3,4,5-Trimethoxyamphetamine Hydrochloride (14). Yield
70%; 1H NMR ä: 1.09 (3H, d, CH3), 2.64 (1H, dd, J ) 13.3; 8.4,
CH2), 2.86 (1H, dd, J ) 13.3; 5.7, CH2), 3.35 (1H, m, CH), 3.69
(3H, s, 6-OCH3), 3.77 (3H, s, 3-OCH3), 3.78 (3H, s, 4-OCH3), 6.68
(1H, s, H (2)), 6.79 (1H, s, H (5)), 7.94 (3H, bs, NH3+); 13C NMR
ä: 17.8 CH3, 34.3 CH2, 47.0 CH, 55.8, 56.1, 56.3 (3OCH3), 98.2
C (5), 115.3, 115.7 C (1) and C (2), 142.4 C (6), 148.6 C (3),
151.6 C (4); EI-MS m/z (%): 225 (M+¥, 11), 182 (100), 167 (32),
151 (15), 139 (8); mp 193-195 °C.
(R,S)-3,4-Dibenzyloxyamphetamine Hydrochloride (15). Yield
56%; 1H NMR ä: 1.08 (3H, d, CH3), 2.59 (1H, dd, J ) 13.4; 8.8,
CH2), 2.93 (1H, dd, J ) 13.4; 5.8, CH2), 3.39 (1H, m, CH), 5.13
(2H, s, 3-OCH2), 5.15 (2H, s, 4-OCH2), 6.77 (1H, dd, J ) 8.2; 1.8,
H (6)), 7.00 (1H, d, J ) 1.8, H (2)), 7.20 (1H, d, J ) 8.2, H (5)),
7.33-7.50 (10H, m, phenyl), 8.07 (3H, bs, NH3+); 13C NMR : 17.6
CH3, 39.6 CH2, 48.0 CH, 70.0 (2OCH2), 114.5, 115.6 C (2) and
C (5), 121.9 C (6), 127.6-128.4 (10CHAr), 129.6 C (1), 137.3,
137.4 (2CAr), 147.1 C (3), 148.1 C (4); EI-MS m/z (%): 348
(M+¥, 5), 181 (12), 91 (100), 65 (14); mp 130-132 °C (lit (45).
mp 130-133 °C).
General Synthetic Procedure for the N-Methylation of the
Amphetamine Derivatives. Compounds 16, 17, and 18 were
synthesized according to a synthetic route published earlier (47).
The preparation of these secondary amines, starting from the
respective primary amines, was preformed by a two-step reaction
pathway, in which the intermediate was a carbamate derivative.
The amine hydrochlorides (11, 12, and 15) (4.5 mmol) were
dissolved in water (30 mL) at 0 °C. A solution of NaOH (0.3 g) in
water (2.5 mL) was then added to the reaction followed by the
addition of ethylchloroformate (0.5 mL, 5.3 mmol). The suspension
was stirred at 0 °C for 3 h, and the reaction was then stopped by
extraction with 3  100 mL of dichloromethane. The organic layer
was dried, and the solvent was evaporated to obtain the corre-
sponding urethane (R-NHCOOEt) (yields around 85%). These
compounds were then reduced to the methylated amine by reaction
with LiAlH4. Briefly, the carbamates (4.1 mmol) were dissolved
in THF (15 mL), and this solution was slowly added to lithium
aluminum hydride (12 mmol) suspended in THF (25 mL), under
N2. The reaction was stirred and heated under reflux for 10 h. The
quenching of the reaction, purification procedure, and the salifi-
cation were performed by the same technique used in the previous
reaction step. The purified compounds were fully characterized with
the following structural features.
(R,S)-3,4-Dimethoxymethamphetamine Hydrochloride (17).
Yield 55%; 1H NMR ä: 1.09 (3H, d, CH3), 2.54 (3H, s, NCH3),
2.56 (1H, dd, J ) 13.2; 8.2, CH2), 3.07 (1H, dd, J ) 13.2; 4.5,
CH2), 3.35 (1H, m, CH), 3.72 (3H, s, 3-OCH3), 3.75 (3H, s,
4-OCH3), 6.74 (1H, dd, J ) 8.2; 1.8, H (6)), 6.86 (1H, d, J )
1.8, H (2)), 6.90 (1H, d, J ) 8.2, H (5)), 8.90 (2H, bs, NH2+);
13C NMR ä: 15.0 CH3, 29.6 NCH3, 37.9 CH2, 55.3 CH,
55.4 (2OCH3), 111.8, 112.9 C (2) and C (5), 121.3 C (6), 128.8
C (1), 147.7 C (3), 148.7 C (4); EI-MS m/z (%): 210 (M+¥, 6),
152 (16), 107 (5), 72 (7), 58 (100); mp 118-120 °C (lit (43). mp
117-119 °C).
(R,S)-3,4-Dibenzyloxymethamphetamine Hydrochloride (18).
Yield 42%; 1H NMR ä: 1.04 (3H, d, CH3), 2.53 (3H, s, NCH3),
2.55 (1H, dd, J ) 13.2; 8.4, CH2), 3.03 (1H, dd, J ) 13.2; 4.3,
CH2), 3.35 (1H, m, CH), 5.10 (2H, s, 3-OCH2), 5.12 (2H, s,
4-OCH2), 6.75 (1H, dd, J ) 8.2; 1.9, H (6)), 6.99 (1H, d, J ) 2.0,
H (2)), 7.01 (1H, d, J ) 8.2, H (5)), 7.29-7.46 (10H, m, phenyl),
8.74 (2H, bs, NH2+); 13C NMR ä: 15.0 CH3, 29.7 NCH3, 37.9
CH2, 55.3 CH, 70.1 (2OCH2), 114.5, 115.7 C (2) and C (5), 121.9
C (6), 127.5-128.4 (10CHAr), 129.4 C (1), 137.2, 137.4 (2CAr),
147.2 C (3), 148.1 C (4); EI-MS m/z (%): 361 (M+¥, 5), 304 (22),
181 (4), 91 (46), 65 (7), 58 (100); mp 152-155 °C.
General Synthetic Procedure for the O-Demethylation. The
process of O-demethylation to obtain the phenolic derivatives
(19-21) was based on a method described earlier (47, 49). The
first step was the transformation of the hydrochloride salts in the
respective free base amines, by dissolving them in water, making
them alkaline with NH3 solution, and extracting with dichlo-
romethane. The di or trihydroxilated compounds 12, 14, and 17
(4.5 mmol) were then dissolved in anhydrous dichloromethane (50
mL) in an inert atmosphere (N2) and at -60 °C. To this solution,
boron tribromide (13 mL of 1 M solution in dichloromethane, 13
mmol) was added, and the reaction was kept at - 60 °C for 10
min and then allowed to reach room temperature for 4 h. The
reaction was quenched by cautious addition of methanol (10 mL),
and the solvent evaporated yielding a residue of the hydrobromide
salt. Compound 19 was obtained as an almost white solid after
recrystallization with acetonitrile. Compound 20 was recrystallized
from dichloromethane as a white solid that quickly turns into a
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dark oil at room temperature and when exposed to air. The data
obtained was in accordance with that described in the literature
(10-13).
(R,S)-3,4-Dihydroxyamphetamine Hydrobromide (19). Yield
57%; 1H NMR ä: 1.08 (3H, d, CH3), 2.46 (1H, dd, J ) 13.4; 8.8,
CH2), 2.77 (1H, dd, J ) 13.4; 5.4, CH2), 3.30 (1H, m, CH), 6.46
(1H, dd, J ) 8.0; 1.9, H (6)), 6.59 (1H, d, J ) 1.9, H (2)), 6.68
(1H, d, J ) 8.0, H (5)), 7.78 (3H, bs, NH3+), 8.85 (2H, bs, 2OH);
13C NMR ä: 17.6 CH3, 39.6 CH2, 48.3 CH, 115.7, 116.5 C (2)
and C (5), 119.9 C (6), 127.2 C (1), 144.2 C (3), 145.2 C (4);
EI-MS m/z (%):168 (M+¥, 8), 151 (12), 124 (42), 123 (70), 107
(8), 84 (62), 80 (62), 79 (21), 77 (97), 66 (100); mp 189-192 °C
(lit (10). mp 193-195 °C).
(R,S)-2,4,5-Trihydroxyamphetamine Hydrobromide (20). Yield
65%; 1H NMR ä: 1.06 (3H, d, CH3), 2.50 (1H, dd, J ) 13.3; 8.6,
CH2), 2.70 (1H, dd, J ) 13.3; 5.5, CH2), 3.38 (1H, m, CH), 6.34
(1H, s, H (2)), 6.44 (1H, s, H (5)), 7.74 (3H, bs, NH3+), 8.80 (3H,
bs, 3OH); 13C NMR ä: 17.8 CH3, 34.7 CH2, 47.3 CH, 103.7 C
(5), 112.3 C (1), 117.9 C (2), 137.6 C (6), 144.6 C (3), 147.9 C
(4); EI-MS m/z (%): 183 (M+¥, 4), 163 (14), 140 (5), 84 (77), 66
(100).
General Synthetic Procedure for the O-Debenzylation. The
synthesis was carried out by catalytic hydrogenolysis of compounds
15 and 18 as described earlier (46). In a flask containing Argon
and 10% Pd/C (300 mg) previously wetted with dry methanol, a
solution of 15 and 18 (2.5 mmol) in methanol (30 mL) was added.
The mixture was then hydrogenated catalytically in a PARR pump,
at room temperature and at 40 psi until no more hydrogen was
consumed, and the reaction ended (approximately 2 h). The
suspension was filtered by suction to eliminate Pd/C, and methanol
was partially evaporated, HCl was added to form the hydrochloride
salt of the catecholic compounds. Acetonitrile was used as the
recrystallization solvent and compound 21 was obtained as a light
brownish oil and used directly.
(R,S)-3,4-Dihydroxymethamphetamine Hydrochloride (21).
Yield 72%; 1H NMR ä: 1.06 (3H, d, CH3), 2.49 (3H, s, NCH3),
2.53 (1H, dd, J ) 13.2; 8.3, CH2), 2.98 (1H, dd, J ) 13.2; 4.2,
CH2), 3.33 (1H, m, CH), 6.45 (1H, dd, J ) 8.0; 1.9, H (6)), 6.60
(1H, d, J ) 1.9, H (2)), 6.67 (1H, d, J ) 8.0, H (5)), 8.03 (2H, bs,
2OH), 8.92 (2H, bs, NH2+); 13C NMR ä: 14.9 CH3, 29.6 NCH3,
37.8 CH2, 55.6 CH, 115.8, 116.7 C (2) and C (5), 120.0 C (6),
127.3 C (1), 144.1 C (3), 145.3 C (4); EI-MS m/z (%): 180 (M+¥,
8), 166 (13), 151 (6), 123 (57), 105 (12), 91 (11), 86 (100), 77
(53), 66 (24).
Biological Methods. Culture of Undifferentiated PC12 Cells.
PC12 cells, derived from a pheochromocytoma of the rat adrenal
medulla, were cultured in RPMI 1640 medium (with l-glutamine
and HEPES) supplemented with 10% (v/v) horse serum, 5% (v/v)
fetal bovine serum (FBS), 50 U/mL penicillin, and 50 mg/mL
streptomycin (final pH at about 7.4), as described before (50).
Cultures were preserved in 75 cm2 flasks at 37 °C in a humidified
incubator containing 95% air and 5% CO2, and passed at least twice
a week. The cells were plated on poly-L-lysine-coated multiwells
at a density of 100 000 cells/cm2 for MTT assays. In what is related
with the study of chromatin condensation, the cells were plated in
coverslips pre-coated with poly-L-lysine at a density of 180 000
cells/cm2. The cells were additionally incubated with MDMA and
its metabolites (placed as aqueous solutions) for more 24 h.
Analysis of Cell Viability. Cell viability was measured by the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
reduction assay (51). Following the incubation of the cells for 24
h with the tested compounds, they were washed with sodium
solution (in mM:140 NaCl, 5 KCl, 1 MgCl2, 1 NaH2PO4, 1.5 CaCl2,
5.6 glucose, and 20 HEPES (pH 7.4)) and incubated further with
0.2 mL of MTT solution (0.5 mg/mL dissolved in sodium solution
containing 1.0 mM of CaCl2) for 2.5 h. The blue formazan
precipitate, produced after the reduction of MTT by cellular
dehydrogenases, was resuspended and dissolved after addition of
0.2 mL of acidic isopropanol (0.04 M of HCl). The capacity of
treated cells in reducing the tetrazolium salt was expressed as a
percentage of absorbance in control cells (ELISA microplate reader
at 570 nm).
Analysis of Chromatin Condensation. The fluorescent probes
SYTO-13 and PI (propidium iodide) were used to evaluate the
morphological evidence of cell death by necrosis and/or apoptosis,
after preincubation of the cells with the compounds in a concentra-
tion close to IC50.
Necrosis and apoptosis were evaluated concomitantly on cultured
PC12 cells after double fluorescence staining using vital fluores-
cence dyes SYTO-13 (a permeant intercalating probe that labels
RNA and DNA in living cells with an UV-excited green-colored
emission) and propidium iodide (a nonpermeant intercalating probe,
which is excluded from viable cells with an UV-excited red
emission). Normal nuclei exhibited loose chromatin colored green
by SYTO-13; apoptotic nuclei exhibited condensed green-colored
chromatin (postapoptotic necrosis or secondary apoptosis (52) was
characterized by nuclei exhibiting the same apoptotic morphological
features, but with red colored chromatin); necrotic cells exhibited
red-colored nuclei with loose chromatin.
The cells were loaded for 3 min with sodium solution containing
SYTO-13 (4 íM) and PI (4 íg/mL). The cells were then visualized
and counted by fluorescence microscopy in a Nikon diaphot
microscope equipped with a Xenon lamp and a FX 64 Omega
Optical triple filter. Apoptotic and necrotic cells were scored by
counting at least 200 nuclei in four or more random different fields
in triplicates from three different experiments.
Statistical Analysis. Data presented are the mean (SEM from
the number of experiments indicated in the Figure legends,
performed in triplicate. For the comparison of MTT reduction
between treated cells and controls, we performed one-way statistical
analysis of variance (ANOVA) followed by the Tukey-Kramer
post-hoc test. For the analysis of chromatin condensation, statistical
analysis was performed by the Kruskal-Wallis test followed by
the Mann-Whitney multiple comparison with Bonferroni correc-
tion. In both cases, significance was accepted at p < 0.05.
Results and Discussion
Chemistry. MDMA and its major metabolites are ring-
substituted phenethylamine derivatives structurally related to
psychomotor stimulant amphetamines and the hallucinogen
mescaline.
The total synthesis of the drug and its main metabolites was
based on the general pathway presented in Figure 2.
Briefly, the synthesis of the target compounds was performed
in a straightforward manner, starting from the appropriate
substituted benzaldehydes (1-5), which were converted into
the corresponding phenylisopropylamines (11-15) Via â-meth-
yl-â-nitrostyrenes (6-10) intermediates. First, a Knoevenagel
condensation between the aldehyde, with the corresponding
aromatic substitution pattern, and nitroethane was carried out,
yielding the nitrostyrene derivatives (53). These compounds
were then reduced to the unsaturated primary amines by lithium
aluminum hydride (LiAlH4). When necessary, the subsequent
N-methylation of the amphetamine derivatives 11, 12, and 15
was accomplished by a two-step reaction path, beginning with
the treatment with ethylchloroformate to provide the N-formyl
derivatives followed by a reduction with LiAlH4 to yield the
designed N-methylated products (16-18). Finally and in order
to obtain the phenolic amphetamine analogous (19-21), com-
pounds 12, 14, and 17 were O-demethylated after reaction with
boron tribromide (BBr3).
Prior to the characterization procedures and biological assays,
all of the compounds containing an amine group were converted
to their hydrochloride or hydrobromide salts, according to the
employed synthetic route and/or stability of the final compound.
Derivative 13 (4-hydroxy-3-methoxyamphetamine), as a
hydrochloride, was also prepared in fairly good yield by
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reductive amination of the ketone 4-hydroxy-3-methoxyphenyl-
acetone (Figure 3) (10).
The synthetic approach leading to the phenolic compounds
19-21 requires protection/deprotection steps to prevent alleged
side reactions. Because the process of deprotection and following
purification seems to be a limitative key step of the designed
synthetic procedure, it was interesting to study different strate-
gies to synthesize compounds 19 and 21 with the main goal of
improving the overall yield. For the protection of the catechol
of the starting material (3,4-dihydroxybenzaldehyde), the fol-
lowing protecting groups were used: benzyl (Bn or -CH2C6H5),
methoxymethyl (MOM), tetrahydropyranyl (THP), and di-tert-
butyldichlorosilyl (DTBS) ethers (54). The yields of these
protection reactions were not significantly different, except for
benzylic ether, which seems to be a good alternative because
the benzylated benzaldehyde was obtained in good yield, and
the deprotected final amines (R-MeDA and N-Me-R-MeDA)
can be easily achieved by hydrogenolysis (a selective, apparently
smoother and cleaner reaction compared to that of boron tribro-
mide demethylation; see Experimental Procedures) (Figure 4).
All of the synthesized compounds were identified by both
NMR and electron impact mass spectroscopy (EI-MS), and their
purity was confirmed using the HPLC systems reported in
Experimental Procedures.
Biological Assays: Analysis of Cell Viability. The putative
neurotoxic effects of this series of compounds were evaluated
by two different types of assays: (i) analysis of PC12 cell
viability after incubation with increasing concentrations of the
tested compounds and (ii) analysis of chromatin fragmentation/
condensation after incubation of PC12 cells with a concentration
close to the respective IC50 values (concentration of the drug
that decreases cell viability by 50%). The cell line selected for
the cytotoxicity studies is derived from a catecholamine-
secreting tumor (pheochromocytoma) of rat adrenal medulla,
which upon exposure to nerve growth factor (NGF) differentiates
into a neuronal phenotype similar to that of the postganglionic
sympathetic (catecholaminergic) nerve-like cell (34). Undif-
ferentiated PC12 cells are commonly used for the screening of
cytotoxicity and to study the disruption by neurotoxicants related
to various aspects of neuronal physiology and biochemistry (55,
56). It is worthwhile to mention that undifferentiated PC12 cells
release more dopamine and less acetylcholine than differentiated
cells (34).
Studies of cell toxicity were performed by analyzing cell-
reducing capacity through the examination of the ability of these
cells to reduce MTT (3-(4,5-dimethylthiazol-2-il)-2,5-diphen-
yltetrazolium). The MTT measures the reducing capacity of the
cells, a parameter dependent upon the maintenance of cellular
metabolic function, thus reflecting cell viability and/or prolifera-
tion. This tetrazolium salt (yellow and soluble) is reduced to
formazan (blue and insoluble) by active cellular dehydrogenases.
The number of metabolically viable cells in the culture was
directly correlated with the amount of formazan dye formed.
Changes in cell viability caused by exposure to MDMA or
its five metabolites were evaluated and compared as shown in
Figure 5. All of the compounds induced a dose-dependent de-
crease in cell viability after 24 h of incubation; however, the
catechol-containing metabolites (19-21) were considerably
more toxic to PC12 cells because their IC50 values are signifi-
cantly lower than the ones of MDA and MDMA, as determined
by the analysis of all of the IC50 values: IC50 158 íM (N-
Me-R-MeDA) < IC50 247 íM (6-OH-R-MeDA) < IC50 416
íM (R-MeDA) , IC50 3365 íM (MDA) < IC50 4464 íM
(MDMA) < IC50 7526 íM (3-O-Me-R-MeDA), decreasing
order of toxicity. The range of concentrations achieved is
believed to occur in ViVo after repeated drug usage (57).
Evaluation of Necrosis and Apoptosis. Apoptosis has been
shown to play a key role in the cytotoxic effects of many drugs,
including amphetamine derivatives (36, 37). However, the
precise role of apoptosis in the toxic effects of MDMA and its
metabolites in dopaminergic cells has not been fully ac-
complished. Thus, upon analysis of cell viability, we attempted
to characterize cell death as apoptotic and/or necrotic, by
studying the morphological changes of the nuclei.
We analyzed the fragmentation/condensation of chromatin,
a characteristic feature of apoptosis, by using the SYTO-13/PI
assay. Apoptotic cells resulted in shrunken, brightly green fluor-
escent nuclei due to SYTO-13 labeling, showing condensed
chromatin with high fluorescence compared with nonapoptotic
cells. Simultaneous labeling with propidium iodide (PI), a non-
permeable fluorescent dye, excluded from the living cells,
allowed the detection of nucleic acids in intact nuclei of mem-
brane-damaged cells (red fluorescence), characteristic of necrotic
cell death. Late or secondary apoptosis was characterized by
SYTO-13 plus PI labeling of fragmented/condensed nuclei.
Figure 2. General synthetic procedure for MDMA and its metabolites. Chemical conditions: (a) EtNO2, NH4CH3COO, reflux; (b) LiAlH4, THF,
reflux; (c) 1. ClCOOC2H5, H2O, NaOH, 0 °C; 2. LiAlH4, THF, reflux; (d) for the methylated compounds (12, 14, 17): BBr3, CH2Cl2, -60 °C; for
the benzylated compounds (15, 18): H2, Pd/C, MeOH. See Experimental Procedures.
Figure 3. Reductive amination route for the synthesis of 3-O-
Me-R-MeDA (13). Chemical conditions: (a) ammonium acetate
(NH4CH3COO) and sodium cyanoborohydride (NaCNBH3) in methanol
(24 h/rt/N2/pH 6).
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To determine the fraction of fragmented/condensed nuclei,
PC12 cells were incubated with the compounds for 24 h in
concentrations in the vicinity of the IC50 values as determined
in Figure 5. Under these conditions, there was a decrease by
15 to 30% in the number of viable cells (Figure 6). It should
be noted that the loss of cell-reducing capacity (ascertained by
the MTT assay) may not correspond immediately to cell death,
as evidenced by the SYTO13/PI assay. Cells may have lost
metabolic activity before showing evidence of a loss of
membrane integrity or nuclear fragmentation or condensation.
All of the compounds tested, with the exception of R-MeDA,
induced fragmentation and condensation of chromatin and,
therefore, apoptosis when compared to the control, as observed
by the labeling with SYTO-13 (Figure 6). MDMA, MDA,
N-Me-R-MeDA, and R-MeDA revealed an increase of necrotic
cell death compared to the control.
By comparing the relative proportion of the cells showing
features of necrosis and apoptosis for each compound, it is
important to highlight that although in a relatively small
percentage N-Me-R-MeDA causes cell death mainly by apop-
tosis (by 6%), MDMA (by 8%) and R-MeDA (by 13.7%) cause
cell death mostly by necrosis, whereas the other compounds
did not induce a predominant type of cell death.
Comparison of features of apoptosis and necrosis observed
for MDMA and its metabolites revealed no significant differ-
ences between the groups and, therefore, no major changes in
the profile of cell death evoked by all of the compounds tested.
Structure-Oxidation-Toxicity Relationships. Because cy-
totoxic effects are frequently ascribed to be related to the
occurrence of redox reactions, standard redox potentials of
MDMA and its metabolites were determined in order to establish
the relationship between the observed cytotoxicity and the
oxidative profile. The electrochemical behavior of the com-
pounds was studied at physiological pH 7.3, at a glassy carbon
working electrode (GCE) using differential pulse, cyclic, and
square wave voltammetry.
From the analysis of the electrochemical data of the drug
and metabolites, it was possible to clearly distinguish two sets
of compounds (Figure 7): one containing the metabolites with
a catecholic group (R-MeDA (19), 6-OH-R-MeDA (20), N-Me-
R-MeDA (21)) and the other including the compounds with a
substituted catechol function (MDA (11), 3-O-Me-R-MeDA
(13), MDMA (16)).
For 6-OH-R-MeDA (20), N-Me-R-MeDA (21), and R-MeDA
(19), two well-defined anodic peaks were observed at physi-
ological pH using differential pulse voltammetry (Figure 7a).
The first peak is related to the oxidation of the catechol group
to o-quinone and occurs at Ep ) -0.11 V for compound 20
Figure 4. Proposed synthetic strategies for the total synthesis of R-MeDA (19) and N-Me-R-MeDA (21) using a benzyl group to protect the
catechol.
Figure 5. Dose-response curves of MDMA and metabolite-induced
cytotoxicity. PC12 cells were incubated with increasing concentrations
of the compounds for 24 h, and the toxic effects were evaluated by the
MTT reduction assay (percentage of MTT reduction relative to the
control). Data are the mean ( SEM of at least three experiments
performed in triplicate.
Figure 6. Analysis of chromatin condensation in PC12 cells exposed
to the six compounds: N-Me-R-MeDA, 6-OH-R-MeDA, R-MeDA (300
íM each), MDA, MDMA, and 3-O-Me-R-MeDA (3 mM each)
incubated for 24 h. SYTO-13 and propidium iodide (PI) were used to
evaluate apoptotic or necrotic cell death. Data are the mean ( SEM of
three experiments performed in triplicate. Statistical significance
compared to the control (in the absence of the drug): **p < 0.01 with
Bonferroni correction is considered very significant.
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and +0.16 V for compounds 19 and 21. Cyclic and square wave
voltammograms recorded for these compounds clearly show the
reversible character of this first electron-transfer oxidation
reaction, which is consistent with the formation of quinonoid
structures. The second anodic wave occurring at more positive
potentials (Figure 7a) could be due to the oxidation of the
quinone side-chain. MDMA (16) presents two well-defined
anodic peaks at physiological pH using differential pulse
voltammetry (Figure 7b). The first, Ep ) +1.06 V, is due to
the removal of one electron from the aromatic ring with the
formation of a radical cation stabilized by the substituents, and
the second peak, Ep ) +1.27 V, could be attributed to the
oxidation of the secondary amine present in the structure. MDA
(11) showed only a single and well-defined anodic wave at
physiological pH, Ep ) +1.07 V (Figure 7b) attributed also to
the removal of one electron from the aromatic ring, the same
oxidation process as in MDMA. For 3-O-Me-R-MeDA (13), a
well-defined anodic peak is observed at physiological pH using
differential pulse voltammetry (Figure 8). This peak, Ep ) +0.43
V, is due to the oxidation of the phenolic group. An indistinct
second wave also appears at ca. +1.15 V (Figure 8), which
might correspond to the formation of the radical aromatic cation.
Regarding the redox potentials obtained for the compounds,
which are summarized in Table 1, it is possible to depict a clear
correlation: all of the catechol-containing metabolites are more
easily oxidized and remarkably more cytotoxic (Figure 5), a
feature that could be intrinsically related with the in situ
formation of electrophilic quinones. In fact, the obtained
electrochemical data allow us to show that the catecholic
metabolites share a common oxidative profile with the formation
of quinones as primary oxidation products, which are highly
reactive with respect to nucleophiles. The quinones can undergo
an intracyclization process through the amine group of the side-
chain, as an available nucleophile, leading to the formation of
leucoaminochromes. Subsequently, these heterocyclic com-
pounds can be easily oxidized to aminochromes. Moreover, the
high predisposition to oxidation of these catecholic compounds,
traduced by its redox potential, can also result in its autoxidation,
leading to the formation of extracellular hydrogen peroxide and
consequently to an increase in cytotoxicity.
Conclusion
The obtained data clearly indicate that some of the metabolites
of MDMA cause stronger effects on PC12 cells than the parent
compound, as shown by the analysis of their cytotoxic profiles.
Given the large ammount of data implicating MDMA in
neurodegeneration, the present results support the hypothesis
that the mechanism of neurotoxicity can be related with
biotransformation after the administration of the drug.
Although N-Me-R-MeDA, 6-OH-R-MeDA, and R-MeDA
have not been undoubtedly established as in ViVo neurotoxic
metabolites of MDMA, it was demonstrated that these metabo-
lites can account for the toxic properties of this drug. Note that
N-Me-R-MeDA, a metabolite that attains human plasma con-
centrations similar to those of MDMA (58), was the most toxic
metabolite, a result that is in agreement with toxicological data
obtained in cardiomyocytes and hepatocytes (9, 59). It is possible
that adducts of these catecholic-containing compounds and major
oxidative metabolites of MDMA could be generated and
participate in its toxic effects (60-62).
Comparing the cytotoxicity of 6-OH-R-MeDA and R-MeDA,
we conclude that the introduction of an hydroxyl group at the
Figure 7. Differential pulse voltammograms in pH 7.3 phosphate
supporting electrolyte of 0.1 mM solutions of (a) (---) 6-OH-R-MeDA,
(âââââ) N-Me-R-MeDA and (s) R-MeDA; (b) (s) MDMA and (âââââ)
MDA. Scan rate 5 mVs-1.
Figure 8. Differential pulse voltammograms in pH 7.3 phosphate
supporting electrolyte of 0.1 mM solutions of (---) R-MeDA, (âââââ)
MDA and (s) 3-O-Me-R-MeDA. Scan rate 5 mVs-1.
Table 1. Redox Potential Values of MDMA and Its Metabolites
compound peak Ep/V vs Ag/AgCl
R-MeDA (19) I 0.16
II 0.89
6-OH-R-MeDA (20) I -0.11
II 1.05
N-Me-R-MeDA (21) I 0.16
II 1.25
3-O-Me-R-MeDA (13) I 0.43
II 1.15
MDMA (16) I 1.06
II 1.27
MDA (11) I 1.07
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ortho position to the amine side chain leads to an increase in
cytotoxic properties. 6-OH-R-MeDA was previously described
as neurotoxic because it has structural similarities with 6-hy-
droxydopamine, a potent neurotoxin that causes long-term
alterations in central monoaminergic systems (13, 19).
All compounds that possess a substituent in the catechol group
seem to be less toxic than those with free aromatic hydroxyl
groups. The ability of these latter compounds to form reactive
o-quinones, leading to the formation of reactive species, is
thought to represent a critical step in their toxicity, as suggested
by previous studies (63, 64). Furthermore, the oxidation of the
metabolites to their respective aminochromes, which are toxic,
must also be taken in consideration (9). Electrochemical results
fully support and explain the differences observed in terms of
the cytotoxicity of the compounds.
N-Methylation enhances cytotoxicity on PC12 cells. In
contrast, O-methylation of the catecholamine-type compounds
seems to be a detoxification step in the metabolism of MDMA
because the resulting compound (3-O-Me-R-MeDA) is signifi-
cantly less toxic than the parent compound and the catecholic
precursors that will undergo O-methylation by the action of
COMT.
It is important to notice that the experimental IC50 values
obtained in the present work (ranging from 150 to 7000 íM)
are in agreement with other similar published in Vitro studies
(59, 61, 62), particularly for the more toxic metabolites.
It was undoubtedly established that metabolism leads to
changes of the redox potential of the parent compound. How-
ever, the authors believe that another physicochemical param-
eter, namely, lipophilicity, also contributes to its toxicity because
a correlation was found between the partition coefficients of
the metabolites and their toxicity as depicted in Figure 9.
The data on chromatin fragmentation/condensation reveal that
the majority of MDMA metabolites significantly increase cell
death by apoptosis. Programmed cell death was previously
proposed to be involved in the neurotoxic effects of MDMA
because the drug induces apoptosis on serotonergic and neo-
cortical neurons (36, 37). If one compares the metabolites and
the drugs used recreationally (MDMA and MDA), the overall
effects of the compounds as apoptosis inducers are quite similar,
and their toxic effects in undifferentiated PC12 cells seem to
be associated with the induction of apoptotic cell death.
Nevertheless, it is important to note that some metabolites also
led to significant death by necrosis. Accordingly, further
experimental approaches are needed to clarify the precise
cytotoxic mechanisms.
Systemic metabolism of MDMA seems to be needed for the
occurrence of neurotoxicity, but the nature of any putative toxic
metabolite is still unknown. Because drug metabolites are
usually more hydrophilic than their parent drug, specific
transporters are presumably needed to take up the neurotoxic
metabolite into the brain (10, 23). These results provide evidence
that the metabolism of MDMA is a key factor for its toxicity
and may prove to be useful in elucidating the amphetamine-
like drug’s putative activities.
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